Calvo JJJ, Ulloa CML, González GAR

Language: Spanish
References: 17
Page:
PDF size: 232.89 Kb.

ABSTRACT

Epilepsy is one of the most common chronic neurological conditions, with an estimated 1.2% of the population having an active diagnosis of epilepsy. This makes epilepsy the most frequent major neurological complication in pregnancy. Management strategies for epileptic women wishing to become pregnant mainly involve family planning and counselling. It is important to inform about contraception, the need to plan the pregnancy, the optimization of antiepileptic drugs, folate supplementation and the possible risks of antiepileptic drugs on the fetus, particularly if valproate is used. Epilepsy is not a contraindication to pregnancy and the patient should be instructed that most pregnancies proceed without any problem, and unnecessary worries should be avoided. It must also be reported that contraceptives have interaction with antiepileptics, due to this there is a risk that the effect will be reduced, either that of contraception or the anticonvulsant effect. Ideally, adequate control of epileptic seizures is sought to plan pregnancy, because it has been shown that women who have not had epileptic seizures in the last 9 months will probably not suffer any change in their condition. It is important to know the pharmacokinetics of antiepileptic drugs during pregnancy, monitor their serum levels, and adjust the dose according to the results. With regard to childbirth, epilepsy is not considered a reason for caesarean delivery unless a seizure occurs during labor. The objective of this review is to demonstrate the importance of managing epilepsy during and prior to pregnancy, with emphasis on the care of women with epilepsy in the prenatal, perinatal, delivery and postpartum stages, as well as to demonstrate the potential fetal risks and the management of antiepileptic drugs during pregnancy.

REFERENCES

1. Yi Li B, Meador K. Epilepsy and Pregnancy.Continuum [internet]. 2022 [citado 20 deenero de 2023]; 28(1): 34-54. Disponible en:https://doi.org/10.1212/CON.0000000000001056

2. Harden C, Lu C. Epilepsy in Pregnancy.Neurologic the Clinics [internet]. 2019 [citado20 de enero de 2023]; 37: 53-62. Disponibleen: https://doi.org/10.1016/j.ncl.2018.09.008

3. Johnson E. Seizures and Epilepsy. Medicalthe Clinics [internet]. 2019 [citado 20 de enerode 2023]; 103 (2): 309-324. Disponible en:https://doi.org/10.1016/j.mcna.2018.10.002

4. Dupont S, Vercueil L. Epilepsy andpregnancy: What should the neurologists do?.Revue Neurologique [internet]. 2021 [citado20 de enero de 2023]; 177(3): 168-179.Disponible en:https://doi.org/10.1016/j.neurol.2021.01.003

5. Bui E. Women´s Issues in Epilepsy.Continuum [internet]. 2022 [citado 20 deenero de 2023]; 28(2): 399-427. Disponibleen:https://doi.org/10.1212/CON.0000000000001126

6. Craig J, Scott S, Leach J. Epilepsy andpregnancy: identifying risks. PracticalNeurology [Internet]. 2021 [citado 20 de enerode 2023]; 22: 98-106. Disponible en:https://doi.org/10.1136/practneurol-2019-002304

7. Tomson T, Battino D, Bromley R, Kochen S,Meador K, Pennell P, Thomas S.Management of epilepsy in pregnancy: areport from the International League AgainstEpilepsy Task Force on Women andPregnancy. ILAE Epileptic Disorders[internet]. 2019 [citado 20 de enero de 2023];21(6): 497-517. Disponible en:https://doi.org/10.1684/epd.2019.1105

8. Błaszczyk B, Miziak B, Pluta R, Czuczwar S.Epilepsy in Pregnancy—ManagementPrinciples and Focus on Valproate.International Journal of Molecular Sciences[internet]. 2021 [citado 20 de enero de 2023];23(3): 1-22. Disponible en:https://doi.org/10.3390/ijms23031369

9. Pennell P, McElrath T. Risks associated withepilepsy during pregnancy and postpartumperiod. Up to Date. 2022 [citado 20 de enerode 2023]; 1-38.

10. Pennell P, McElrath T. Management ofepilepsy during preconception, pregnancy,and the postpartum period. Up to Date. 2022;1-38.

11. Stephen L, Harden C, Tomson T, Brodie M.Management of epilepsy in women. LancetNeurology [internet]. 2019 [citado 20 de enerode 2023]; 18(5): 481-491. Disponible en:http://dx.doi.org/10.1016/S1474-4422(18)30495-2

12. Joung W. Pregnancy and ChildbirthExperiences of Women with Epilepsy: APhenomenological Approach. Asian NursingResearch [internet]. 2019 [citado 20 de enerode 2023]; 13: 122-129. Disponible en:https://doi.org/10.1016/j.anr.2019.02.005

13. Pennell P, French J, May R. Changes inSeizure Frequency and Antiepileptic Therapyduring Pregnancy. New England Journal ofmedicine [internet]. 2020 [citado 20 de enerode 2023]; 383(26): 2547-2556. Disponible en:https://doi.org/10.1056/NEJMoa2008663

14. Jeon J, Bae J, Kim K, Cho Y. Pregnancy andEpilepsy: a Korean Tertiary Epilepsy CenterReview. Journal of Korean Medical Science[internet]. 2020 [citado 20 de enero de 2023];35(19): 1-9. Disponible en:https://doi.org/10.3346/jkms.2020.35.e119

15. Arfman I, Wammes􀇦van der Heijden E, terHorst P, Lambrechts D, Wegner I, TouwD.Therapeutic Drug Monitoring ofAntiepileptic Drugs in Women with EpilepsyBefore, During, and After Pregnancy. ClinicalPharmacokinetics [internet]. 2020 [citado 20de enero de 2023]; 59: 427-445. Disponibleen: https://doi.org/10.1007/s40262-019-00845-2

16. Macfarlae A, Greenhalgh T. Sodium valproatein pregnancy: what are the risks and shouldwe use a shared decision-making approach?.BMC Pregnancy and Childbirth [internet].2018 [citado 20 de enero de 2023]; 18(200):1-11. Disponible en:https://doi.org/10.1186/s12884-018-1842-x

17. Kaplan Y, Demir O. Use of Phenytoin,Phenobarbital Carbamazepine,Levetiracetam Lamotrigine and Valproate inPregnancy and Breastfeeding: Risk of MajorMalformations, Dose-dependency,Monotherapy vs Polytherapy,Pharmacokinetics and Clinical Implications.Current Neuropharmacology [internet]. 2021[citado 20 de enero de 2023]; 19: 1805-1824.Disponible en:https://doi.org/10.2174/1570159X19666210211150856